PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

MJM Uijen, YHW Derks, RIJ Merkx… - European journal of …, 2021 - Springer
In the past decade, a growing body of literature has reported promising results for prostate-
specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate …

PSMA expression in solid tumors beyond the prostate gland: ready for theranostic applications?

C Lauri, L Chiurchioni, VM Russo, L Zannini… - Journal of Clinical …, 2022 - mdpi.com
In the past decades, the expanding use of prostate-specific membrane antigen (PSMA)
imaging for prostate cancer has led to the incidental detection of a lot of extra-prostatic …

Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study

X Shi, H Xing, X Yang, F Li, S Yao, J Congwei… - European Journal of …, 2021 - Springer
Purpose This study aimed to compare the performance of 68 Ga-labelled fibroblast
activating protein inhibitor (FAPI) PET and 18 F-FDG PET for imaging of hepatic tumours …

Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules

X Shi, H Xing, X Yang, F Li, S Yao, H Zhang… - European journal of …, 2021 - Springer
Abstract Purpose 68 Ga-FAPI-04 is a rapidly evolving PET tracer for whole-body imaging in
a variety of cancers. We aimed to evaluate the diagnostic performance of 68 Ga-FAPI-04 for …

Fibroblast-activated protein inhibitor PET/CT: cancer diagnosis and management

S Kuyumcu, Y Sanli, RM Subramaniam - Frontiers in oncology, 2021 - frontiersin.org
Fibroblast activation protein (FAP), overexpressed on cancer-associated fibroblasts (CAFs),
is a novel target for molecular imaging of various tumors. Recently, the development of …

PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617

Q Lu, Y Long, K Fan, Z Shen, Y Gai, Q Liu… - European journal of …, 2022 - Springer
Objective Hepatocellular carcinoma (HCC) is a malignant tumor associated with high
morbidity and mortality rates. In many non-prostate solid tumors such as HCC, prostate …

Can PSMA-targeting radiopharmaceuticals be useful for detecting hepatocellular carcinoma using positron emission tomography? An updated systematic review and …

A Rizzo, M Racca, D Albano, F Dondi, F Bertagna… - Pharmaceuticals, 2022 - mdpi.com
Background: Several studies proposed the use of positron emission tomography (PET) with
Prostate-Specific Membrane Antigen (PSMA)-targeting radiopharmaceuticals in …

PSMA-targeting positron emission agents for imaging solid tumors other than non-prostate carcinoma: a systematic review

C Van de Wiele, M Sathekge, B De Spiegeleer… - International journal of …, 2019 - mdpi.com
Despite its name, prostate-specific membrane antigen (PSMA) has been shown using
immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a …

Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions of 68Ga-PSMA PET/CT Scans

S Rijnsdorp, MJ Roef, AJ Arends - Diagnostics, 2021 - mdpi.com
Functional imaging with 68Ga prostate-specific membrane antigen (PSMA) and positron
emission tomography (PET) can fulfill an important role in treatment selection and …

[PDF][PDF] PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga

SM Thompson, G Suman… - Hepatology …, 2022 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is a validated target for molecular diagnostics
and targeted radionuclide therapy. Our purpose was to evaluate PSMA expression in …